ISEE News and Press, IVERIC bio Inc. From 03/23/23

2023-03-23 14:37:16 ET Summary Iveric Bio has a promising pipeline of products, including its complement C5 inhibitor, avacincaptad pegol (ACP), which has achieved impressive results in phase 3 clinical trials. The company's recent post-hoc analysis from its GATHER clinical trial ...

Image source: The Motley Fool. IVERIC Bio (NASDAQ: ISEE) Q4 2022 Earnings Call Mar 01, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: IVERIC Bio (ISEE) Q4 2022 Earnings Call Transcript

Gainers: Reata Pharmaceuticals ( RETA ) +175% . OncoSec Medical ( ONCS ) +94% . B&G Foods ( BGS ) +30% . Nerdy ( NRDY ) +29% . SCYNEXIS ( SCYX ) +29% . Blackboxstocks ( BLBX ) +29% . Red Robin Gourmet Burgers ( RRGB ...

IVERIC bio, Inc. (ISEE) Q4 2022 Results Conference Call March 01, 2023 08:00 AM ET Company Participants Kathy Galante - Investor Relations Glenn Sblendorio - Chief Executive Officer Pravin Dugel - President Keith Westby - Chief Operating Officer David Carroll -...

Iveric bio ( NASDAQ: ISEE ) said data from a post-hoc time-to-event analysis from trials suggested a reduction in rate of vision loss with avacincaptad pegol (ACP) of up to 59% compared to sham at one year. The GATHER1 and GATHER2 trials were evaluating ACP 2 mg versus sham treat...

IVERIC bio press release ( NASDAQ: ISEE ): Q4 GAAP EPS of -$0.47 misses by $0.10 . As of December 31, 2022, the company had approximately $646.8M in cash, cash equivalents and available-for-sale securities. The company estimates that its cash, cash equivalents, available-f...

- FDA Accepts Filing of New Drug Application and Grants Priority Review for Avacincaptad Pegol (ACP) for the Treatment of Geographic Atrophy; PDUFA Goal Date is August 19, 2023 - - Post-hoc Time-to-Event Analysis of ACP GATHER Trials Signals up to 59% Risk Reduction in Rate of Vision Lo...

- Post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months - - Analysis to be presented at the ARVO Annual Meeting from April 23-27, 2023 - IVERIC bio, Inc. (Nasdaq: ISEE) today announced an exploratory...

IVERIC bio ( NASDAQ: ISEE ) is scheduled to announce Q4 earnings results on Wednesday, March 1st, before markets open. The consensus EPS Estimate is -$0.37 (-27.6% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revisio...

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7, 2023, at 2:50 p.m. Eastern Time. Investors a...